All In Biotech

Drug Trial Radar · NCT07547813

A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD328 in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Feb 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • LAD328Drug

    LAD328 administered intravenously.

  • PlaceboOther

    Placebo administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55)Time frame: At Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alm Site 1

    Warsaw, Masovian Voivodeship, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.